Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Seelos Therapeutics Inc (SEEL) USD0.001

Sell:$1.94 Buy:$1.96 Change: $0.01 (0.51%)
Market closed |  Prices as at close on 16 September 2021 | Switch to live prices |
Sell:$1.94
Buy:$1.96
Change: $0.01 (0.51%)
Market closed |  Prices as at close on 16 September 2021 | Switch to live prices |
Sell:$1.94
Buy:$1.96
Change: $0.01 (0.51%)
Market closed |  Prices as at close on 16 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of products that address unmet needs in central nervous system (CNS) disorders and other rare disorders. The Company’s lead programs SLS-002 for the treatment of acute suicidal ideation and behavior (ASIB) in depressive disorder (MDD), and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS). SLS-005 for the potential treatment of Sanfilippo Syndromes, which is being explored. It is also developing several preclinical programs, including SLS-010, an oral histamine H3A receptor antagonist that shows promising activity in narcolepsy and related disorders, and SLS-012, an injectable therapy for post-operative pain management. The Company’s ongoing programs include SLS-004, SLS-006, SLS-007, and SLS-008.

Contact details

Address:
300 PARK AVENUE, 2ND FLOOR
NEW YORK
10022
United States
Telephone:
+1 (646) 2932100
Website:
https://seelostherapeutics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SEEL
ISIN:
US81577F1093
Market cap:
$191.33 million
Shares in issue:
102.32 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Raj Mehra
    Chairman of the Board, President, Chief Executive Officer
  • Michael Golembiewski
    Chief Financial Officer
  • Anthony Marciano
    Chief Communications Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.